No Data
No Data
Cube Pharmaceuticals (003020.SZ) reported first-quarter results, net profit of 30.3722 million yuan, a year-on-year decrease of 54.08%
Cube Pharmaceuticals (003020.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Market Cap Increased by CN¥496m, Insiders Receive a 60% Cut
Key Insights Hefei Lifeon Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion The top 2 shareholders own 54% of the company Institutions own 15% of H
Cube Pharmaceuticals (003020.SZ) announced its 2023 annual results, with net profit of 227 million yuan, an increase of 8.33%
Cube Pharmaceutical (003020.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 1...
Cube Pharmaceuticals (003020.SZ): Mesalazine enteric tablet drug registration and marketing license application accepted
On February 26, Gelonghui Pharmaceutical (003020.SZ) announced that recently, Hefei Cube Pharmaceutical Co., Ltd. received a “Notice of Acceptance” for the registration and marketing license application for mesalazine enteric tablets issued by the State Drug Administration. Mesalazine is a non-steroidal anti-inflammatory drug that can inhibit the synthesis of prostaglandins that cause inflammation and the formation of inflammatory mediators leukotriene, thereby significantly inhibiting inflammation of the intestinal mucosa. The product applying for marketing approval is mesalazine enteric tablets, which release mesalazine in the intestines after oral administration. They are suitable for the treatment of acute episodes of ulcerative colitis and maintenance to prevent recurrence
Cube Pharmaceuticals (003020.SZ): Application for marketing registration of tampiol raw materials accepted
Cube Pharmaceutical (003020.SZ) issued an announcement. Recently, the company received Danpi issued by the State Drug Administration...
Cube Pharmaceuticals (003020.SZ): Application for marketing registration of propmecaine hydrochloride as an API was accepted
On February 19, Gelonghui Pharmaceutical (003020.SZ) announced that recently, Hefei Cube Pharmaceutical Co., Ltd. (received the “Notice of Acceptance” of the application for marketing registration of propmecaine hydrochloride raw materials issued by the State Drug Administration. Promethacaine hydrochloride is a potent ester surface anesthetic. Its preparation, propmecaine hydrochloride eye drops, is clinically mainly used for surface ophthalmic anesthesia, etc., and is a fast-acting local anesthetic. As of the announcement date, there are no imported API registrations for promecaine hydrochloride APIs. In addition to the company, there are currently five domestic API companies registered and filed. Three of them have a registration status of “A
No Data